Seeking Alpha

Amicus Therapeutics (FOLD) says it's achieved positive preliminary results from its ongoing...

Amicus Therapeutics (FOLD) says it's achieved positive preliminary results from its ongoing phase 2 open-label drug-drug interaction study to evaluate the safety and effects of AT2220, co-administered with enzyme replacement therapy for Pompe disease. Shares -1.5% AH.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs